Smart Inhalers Market Size, Trends, Growth & Outlook

Smart Inhalers Market by Product (Inhalers and Nebulizers), Indication (Asthma and COPD), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2019 - 2026

Industry: Life Science | Report ID: FAMI-0034 | Published on: Sep, 2019 | View: 1309 | Share:         

Request Sample Enquire Before Buying Request Discount

*As the coronavirus disease (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

  • Report Descripton
  • Table Of Content
  • Request Methodology
  • Request Customization

 The global smart inhalers market size was valued at $34 million in 2018 and is estimated to reach $1,406 million by 2026, growing at a CAGR of 58.4% from 2019 to 2026. Smart inhalers are clip-on sensors, also known as connected inhalers, which are attached to the traditional inhalers. They are used to track the medication, dosage, and time taken for each dose linked wirelessly to the cloud. These inhalers are part of “Internet of Things,” thus providing correct use of the medication, improved adherence to the inhaler, and better health outcomes. Doctors and patients can easily benefit from the use of smart inhalers as they monitor the dosage and provide reminders at the time of dose, which can be recorded for understanding the patient’s daily routine.

The global smart inhalers market is analyzed under three different scenarios, namely, moderate growth, rapid growth, and diminishing growth. Market growth is attributed to the rapid increase in the incidence of respiratory diseases, rise in air pollution, and growth in healthcare burden, owing to higher cases of asthma and COPD. In addition, expected increase in adherence to smart inhalers is another major factor that drives the growth of the smart inhalers market. However, limited availability of smart inhalers, high cost of asthma and COPD treatment, and resistance toward adoption of smart inhalers are expected to hinder the market growth.

The market is segmented on the basis of product, indication, end user, and geography. By product, it is segmented into inhalers and nebulizers. Inhalers dominates the market, which is further divided into dry powder inhalers (DPIs) and metered dose inhalers (MDIs). Based on indication, smart inhalers are bifurcated into asthma and COPD.

Based on distribution channel, it is divided into hospitals, retail pharmacies, and online pharmacies. In terms of geography, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America was the leading revenue-generating region, whereas Asia-Pacific is projected to grow at the high CAGR, owing to rise in demand for smart inhalers and increase in COPD and asthma cases.

KEY BENEFITS FOR STAKEHOLDERS

 The study provides an in-depth analysis of the global smart inhalers market along with the current trends and future estimations to elucidate the imminent investment pockets.
 A quantitative analysis from 2019 to 2026 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
 In-depth analysis of the market based on products such as inhalers and nebulizers is carried out in the report.
 The global smart inhalers market scenario is comprehensively analyzed in accordance to the key cities.

KEY MARKET SEGMENTS

By Product

• Inhalers
o Metered Dose Inhalers
o Dry Powder Inhalers
• Nebulizers

By Indication

• Hospitals
• Ambulatory Surgical Centers
• Others

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o India
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT (DEVICE PROVIDERS)

• AstraZeneca, plc.
• GlaxoSmithKline, plc
• Novartis International AG
• Adherium Limited
• Boehringer Ingelheim Group
• Cohero Health Group
• Vectura Group, plc.
• Opko Health Group 
• Teva Pharmaceutical Industries Ltd.
• ResMed Inc.

Get a sample pages of this report Click here

CHAPTER 1:    INTRODUCTION

1.1.    Report description
1.2.    Research methodology

1.2.1.    Secondary research
1.2.2.    Primary research
1.2.3.    Analyst tools & models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    Key findings

2.1.1.    Top investment pockets

2.2.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope
3.2.    Key forces shaping smart Inhalers market

3.2.1.    Moderate bargaining power of suppliers
3.2.2.    High bargaining power of buyers
3.2.3.    High threat of new entrants
3.2.4.    Moderate threat of substitutes
3.2.5.    High intensity of rivalry

3.3.    Value Chain Analysis
3.5.    Industry pain point analysis
3.6.    Patent Analysis
3.7.    Market share analysis
3.8.    Market Dynamics

3.8.1.    Drivers

3.8.1.1.    Increase in Air Pollution
3.8.1.2.    Increase In Population Susceptible To Indoor Air Pollutants
3.8.1.3.    Increasing Prevalence Of COPD and Asthma ly

3.8.2.    Restraints

3.8.2.1.    Misusing Data And Data Privacy
3.8.2.2.    Overall High Cost Of Asthma And COPD Treatment

3.8.3.    Opportunities

3.8.3.1.    Increased Focus Towards Advanced Treatment Protocols

CHAPTER 4:    SMART INHALERS MARKET, BY PRODUCT

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Inhalers

4.2.1.    Key market trends and opportunities
4.2.2.    Market size and forecast
4.2.3.    Market analysis, by country

4.2.3.1.    Dry Powder Inhalers
4.2.3.2.    Metered Dose Inhalers

4.3.    Nebulizers

4.3.1.    Key market trends and opportunities
4.3.2.    Market size and forecast
4.3.3.    Market analysis, by country

CHAPTER 5:    SMART INHALERS MARKET, BY INDICATION

5.1.    Overview

5.1.1.    Market size and forecast

5.2.    Asthma

5.2.1.    Market size and forecast
5.2.2.    Market analysis, by country

5.3.    COPD

5.3.1.    Market size and Forecast
5.3.2.    Market analysis, by country

CHAPTER 6:    SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL

6.1.    Overview

6.1.1.    Market size and forecast

6.2.    Hospital pharmacies

6.2.1.    Market size and forecast
6.2.2.    Market analysis, by country

6.3.    Retail Pharmacies

6.3.1.    Market size and forecast
6.3.2.    Market analysis, by country

6.4.    Online Pharmacies

6.4.1.    Market size and forecast
6.4.2.    Market analysis, by country

CHAPTER 7:    SMART INHALERS MARKET, BY REGION

7.1.    Overview

7.1.1.    Market size and forecast

7.2.    North America

7.2.1.    Key market trends and opportunities
7.2.2.    North America market size and forecast, by product type
7.2.3.    North America market size and forecast, by indication
7.2.4.    North America market size and forecast, by distribution channel
7.2.6.    North America market size and forecast, by country

7.2.6.1.    U.S. market size and forecast, by product type
7.2.6.2.    U.S. market size and forecast, by indication
7.2.6.3.    U.S. market size and forecast, by distribution channel
7.2.6.5.    Canada market size and forecast, by product type
7.2.6.6.    Canada market size and forecast, by indication
7.2.6.7.    Canada market size and forecast, by distribution channel
7.2.6.8.    Mexico market size and forecast, by product type
7.2.6.9.    Mexico market size and forecast, by indication
7.2.6.10.    Mexico market size and forecast, by distribution channel

7.3.    Europe

7.3.1.    Key market trends and opportunities
7.3.2.    Europe market size and forecast, by product type
7.3.3.    Europe market size and forecast, by indication
7.3.4.    Europe market size and forecast, by distribution channel
7.3.5.    Europe market size and forecast, by country

7.3.5.1.    Germany market size and forecast, by product type
7.3.5.2.    Germany market size and forecast, by indication
7.3.5.3.    Germany market size and forecast, by distribution channel
7.3.5.4.    France market size and forecast, by product type
7.3.5.5.    France market size and forecast, by indication
7.3.5.6.    France market size and forecast, by distribution channel
7.3.5.8.    UK market size and forecast, by product type
7.3.5.9.    UK market size and forecast, by indication
7.3.5.10.    UK market size and forecast, by distribution channel
7.3.5.11.    Italy market size and forecast, by product type
7.3.5.12.    Italy market size and forecast, by indication
7.3.5.13.    Italy market size and forecast, by distribution channel
7.3.5.14.    Spain market size and forecast, by product type
7.3.5.15.    Spain market size and forecast, by indication
7.3.5.16.    Spain market size and forecast, by distribution channel
7.3.5.17.    Rest of Europe market size and forecast, by product type
7.3.5.18.    Rest of Europe market size and forecast, by indication
7.3.5.19.    Rest of Europe market size and forecast, by distribution channel

7.4.    Asia-Pacific

7.4.1.    Key market trends and opportunities
7.4.2.    Asia-Pacific market size and forecast, by product type
7.4.3.    Asia-Pacific market size and forecast, by indication
7.4.4.    Asia-Pacific market size and forecast, by distribution channel
7.4.5.    Asia-Pacific market size and forecast, by country

7.4.5.1.    Japan market size and forecast, by product type
7.4.5.2.    Japan market size and forecast, by indication
7.4.5.3.    Japan market size and forecast, by distribution channel
7.4.5.4.    China market size and forecast, by product type
7.4.5.5.    China market size and forecast, by indication
7.4.5.6.    China market size and forecast, by distribution channel
7.4.5.7.    India market size and forecast, by product type
7.4.5.8.    India market size and forecast, by indication
7.4.5.9.    India market size and forecast, by distribution channel
7.4.5.10.    Australia market size and forecast, by product type
7.4.5.11.    Australia market size and forecast, by indication
7.4.5.12.    Australia market size and forecast, by distribution channel
7.4.5.13.    Rest of Asia-Pacific market size and forecast, by product type
7.4.5.14.    Rest of Asia-Pacific market size and forecast, by indication
7.4.5.15.    Rest of Asia-Pacific market size and forecast, by distribution channel

7.5.    LAMEA

7.5.1.    Key market trends and opportunities
7.5.2.    LAMEA market size and forecast, by product type
7.5.3.    LAMEA market size and forecast, by indication
7.5.4.    LAMEA market size and forecast, by distribution channel
7.5.5.    LAMEA market size and forecast, by country

7.5.5.1.    Brazil market size and forecast, by product type
7.5.5.2.    Brazil market size and forecast, by indication
7.5.5.3.    Brazil market size and forecast, by distribution channel
7.5.5.4.    South Africa market size and forecast, by product type
7.5.5.5.    South Africa market size and forecast, by indication
7.5.5.6.    South Africa market size and forecast, by distribution channel
7.5.5.7.    Rest of LAMEA market size and forecast, by product type
7.5.5.8.    Rest of LAMEA market size and forecast, by indication
7.5.5.9.    Rest of LAMEA market size and forecast, by distribution channel

CHAPTER 8:    COMPANY PROFILES

8.1.    Adherium Limited

8.1.1.    Company overview
8.1.2.    Company snapshot
8.1.3.    Operating business segments
8.1.4.    Product portfolio
8.1.5.    Business performance
8.1.6.    Key strategic moves and developments

8.2.    AstraZeneca PLC

8.2.1.    Company overview
8.2.2.    Company snapshot
8.2.3.    Operating business segments
8.2.4.    Product portfolio
8.2.5.    Business performance
8.2.6.    Key strategic moves and developments

8.3.    Boehringer Ingelheim group

8.3.1.    Company overview
8.3.2.    Company snapshot
8.3.3.    Operating business segments
8.3.4.    Business performance
8.3.5.    Key strategic moves and developments

8.4.    Cohero Health, Inc.

8.4.1.    Company overview
8.4.2.    Company snapshot
8.4.3.    Product portfolio
8.4.4.    Business performance
8.4.5.    Key strategic moves and developments

8.5.    GlaxoSmithKline plc

8.5.1.    Company overview
8.5.2.    Company snapshot
8.5.3.    Operating business segments
8.5.4.    Product portfolio
8.5.5.    Business performance
8.5.6.    Key strategic moves and developments

8.6.    Novartis International AG

8.6.1.    Company overview
8.6.2.    Company snapshot
8.6.3.    Operating business segments
8.6.4.    Product portfolio
8.6.5.    Business performance
8.6.6.    Key strategic moves and developments

Select License Type
  • Single User License $5370 USD
  • Multi-User License $6450 USD
  • Corporate User License $8995 USD

Our Clients

  • +1 518-300-1215Mon-Fri, 24Hrs
  • [email protected]We reply within an hours
  • Albany,
    NY, USA.